Table 3 Changes of disease activities and medications
|  | Naïve group (n = 25) | Switch group (n = 11) | ||||
|---|---|---|---|---|---|---|
Variable | Baseline | 6 months | 12 months | Baseline | 6 months | 12 months |
DAS28-ESR | 3.60 ± 0.17 | 3.55 ± 0.14 | 3.57 ± 0.16 | 4.15 ± 0.32 | 4.07 ± 0.32 | 3.93 ± 0.30 |
SDAI | 6.90 ± 1.00 | 7.34 ± 0.99 | 7.36 ± 0.99 | 9.93 ± 1.38 | 10.1 ± 2.00 | 9.52 ± 2.09 |
MTX (%) | 60.0 | 60.0 | 60.0 | 45.5 | 45.5 | 45.5 |
MTX dose (mg/week) | 8.1 ± 0.9 | 7.9 ± 1.0 | 7.7 ± 1.0 | 7.2 ± 1.4 | 7.2 ± 1.4 | 7.2 ± 1.4 |
PSL (%) | 32.0 | 28.0 | 32.0 | 54.5 | 54.5 | 63.6 |
PSL dose (mg/day) | 5.3 ± 1.4 | 4.7 ± 1.0 | 4.0 ± 0.9 | 3.2 ± 0.6 | 3.2 ± 0.6 | 3.4 ± 0.6 |
bDMARDs (%) | 32.0 | 32.0 | 32.0 | 54.5 | 54.5 | 54.5 |
csDMARDs (%) | 36.0 | 40.0 | 40.0 | 27.3 | 27.3 | 27.3 |